US equities
|
MU
$1,042.52
▼-4.18%
NVDA
$230.63
▼-2.88%
SNDK
$1,611.83
▼-4.76%
AMD
$617.41
▼-4.40%
INTC
$106.19
▼-6.12%
SPCX
$162.14
▼-3.26%
META
$719.05
▼-0.31%
MSFT
$521.31
▼-1.60%
MU
$1,042.52
▼-4.18%
NVDA
$230.63
▼-2.88%
SNDK
$1,611.83
▼-4.76%
AMD
$617.41
▼-4.40%
INTC
$106.19
▼-6.12%
SPCX
$162.14
▼-3.26%
META
$719.05
▼-0.31%
MSFT
$521.31
▼-1.60%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Paradromics Inc.
Paradromics Demonstrates Four Years of Stable Neural Recording in Major Brain-Computer Interface Durability Milestone
Today 9:03 EDT
From
Paradromics Inc.
Via
Business Wire
Paradromics Achieves Real-Time Speech with Connexus® Brain-Computer Interface
September 14, 2026
From
Paradromics Inc.
Via
Business Wire
Paradromics Receives FDA Approval to Expand BCI Access to Personal Computing Devices in Connect-One™ Clinical Study
August 26, 2026
From
Paradromics Inc.
Via
Business Wire
Paradromics Appoints William J. Marks, Jr., MD, MS-HCM, as Chief Clinical Officer
July 07, 2026
From
Paradromics Inc.
Via
Business Wire
Paradromics and University of Michigan Complete First Connexus® BCI Implantation for the FDA-Approved Connect-One Clinical Study
June 17, 2026
From
Paradromics Inc.
Via
Business Wire
Paradromics Receives FDA Approval for the Connect-One Clinical Study with the Connexus® Brain-Computer Interface
November 20, 2025
From
Paradromics Inc.
Via
Business Wire